{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-098489","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.937394+00:00","generated_at":"2026-05-15T18:14:38.503346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Septerna posts Q4 net loss $10.7M, highlights positive Phase 1 data for SEP-631","bullets":["Phase 1 data: SEP-631 well-tolerated, once-daily oral dosing, complete wheal inhibition at 10 mg; Phase 2b in CSU planned H2 2026.","SEP-479 PTH1R agonist on track for Phase 1 initiation in first half of 2026.","Cash $548.7M at Dec 31, 2025; runway at least into 2029 (includes $195M upfront from Novo Nordisk).","Q4 2025 revenue $24.1M (collaboration revenue); net loss $10.7M vs $20.7M loss in Q4 2024.","Appointed Mark A. Wilson as chief legal officer in January 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-098489","json":"https://secwatch.observer/filing/0001193125-26-098489.json","markdown":"https://secwatch.observer/filing/0001193125-26-098489.md","text":"https://secwatch.observer/filing/0001193125-26-098489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526098489/0001193125-26-098489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526098489/sepn-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:14:38.503346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9573f0a7f5ff929eb4bf8120d356bb84428637cb","claim":"Septerna, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $24.1 million for the fourth quarter of 2025 and $46.0 million for the full year ended December 31, 2025, net income Net loss was $10.7 million for the fourth quarter of 2025 and $48.9 million for the full year ended December 31, 2025.","evidence_excerpt":"On March 9, 2026, Septerna, Inc. (the “Company”) announced its financial results and business highlights for the fourth quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526098489/0001193125-26-098489-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$24.1 million for the fourth quarter of 2025 and $46.0 million for the full year ended December 31, 2025"},{"label":"Net income","value":"Net loss was $10.7 million for the fourth quarter of 2025 and $48.9 million for the full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}